未校正原生T1 mapping序列对自身免疫性肝炎肝纤维化与炎症的诊断准确性:以组织病理学为参考标准的前瞻性研究
这项前瞻性研究纳入33例自身免疫性肝炎患者,在活检后3个月内行包含T1 mapping的多参数肝脏MRI,以标准化组织病理学评分(纤维化F0-F4、炎症活动度PPA0-4)为参考标准。T1 mapping值在进展期纤维化(F3-4)、显著纤维化(F2-4)及显著炎症活动(PPA2-4)患者中均显著升高,检测显著纤维化AUC 0.856、进展期纤维化AUC 0.835、显著炎症活动AUC 0.763。作者认为该快速、简便、未校正的非对比T1 mapping序列诊断性能令人满意,可能作为监测疾病活动的无创影像生物标志物。
要点
- 未校正非对比T1 mapping在自身免疫性肝炎中检测显著纤维化AUC 0.856、进展期纤维化AUC 0.835。
- 检测显著炎症活动(PPA2-4)的AUC为0.763,T1值在PPA0-1与PPA2-4间差异p=0.048。
- T1值在F0-2与F3-4间差异p<0.015,在F0-1与F2-4间差异p<0.005。
核心结论
- 快速、简便、未校正的非对比T1 mapping序列与组织病理学相比,在检测自身免疫性肝炎患者显著组织炎症和纤维化方面显示出令人满意的诊断性能,可能是监测此类患者疾病活动的无创影像生物标志物。
研究设计与样本
- 前瞻性研究,3年内纳入33例自身免疫性肝炎患者,采用包含T1 mapping的多参数肝脏MRI方案,活检在成像前最多3个月内完成,以标准化组织病理学纤维化评分(F0-F4)和炎症活动度评分(PPA0-4)为参考标准,统计方法包括独立t检验、Mann-Whitney U检验和ROC分析。
诊断标准与关键数值
- T1 mapping检测显著纤维化(F0-1 vs F2-4)的AUC为0.856。
- T1 mapping检测进展期纤维化(F0-2 vs F3-4)的AUC为0.835。
- T1 mapping检测显著炎症活动(PPA0-1 vs PPA2-4)的AUC为0.763。
- T1值在进展期纤维化(F0-2 vs F3-4)患者中显著更高,p<0.015。
- T1值在显著纤维化(F0-1 vs F2-4)患者中显著更高,p<0.005;在显著炎症活动(PPA0-1 vs PPA2-4)患者中显著更高,p=0.048。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: There is an unmet clinical need for non-invasive imaging biomarkers that could replace liver biopsy in the management of patients with autoimmune hepatitis (AIH). In this study, we sought to evaluate the diagnostic accuracy of a simple uncorrected, non-contrast T1 mapping for detecting fibrosis and inflammation in AIH patients using histopathology as a reference standard.
MATERIAL AND METHODS: Over 3 years, 33 patients with AIH were prospectively studied using a multiparametric liver MRI protocol which included T1 mapping. Biopsies were performed up to 3 months before imaging, and a standardized histopathological score for fibrosis (F0-F4) and inflammatory activity (PPA0-4) was used as a reference. Statistical analysis included independent t test, Mann-Whitney U-test, and ROC (receiver operating characteristic) analysis.
RESULTS: T1 mapping values were significantly higher in patients with advanced fibrosis (F0-2 vs. F3-4; p < 0.015), significant fibrosis (F0-1 vs. F2-4; p < 0.005), and significant inflammatory activity (PPA 0-1 vs. PPA 2-4 p = 0.048). Moreover, the technique demonstrated a good diagnostic performance in detecting significant (AUC 0.856) and advanced fibrosis (AUC 0.835), as well as significant inflammatory activity (AUC 0.763).
CONCLUSION: A rapid, simple, uncorrected, non-contrast T1 mapping sequence showed satisfactory diagnostic performance in comparison with histopathology for detecting significant tissue inflammation and fibrosis in AIH patients, being a potential non-invasive imaging biomarker for monitoring disease activity in such individuals.
引用
- Gomes NBN, Torres US, Caiado AHM, et al. Diagnostic accuracy of an uncorrected native T1 mapping sequence for liver fibrosis and inflammation in autoimmune hepatitis: a prospective study using histopathology as reference standard. Radiol Med. 2024. PMID: 39106024. doi:10.1007/s11547-024-01863-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。